↓ Skip to main content

Indacaterol, a once-daily beta2 -agonist, versus twice-daily beta2 -agonists or placebo for chronic obstructive pulmonary disease

Overview of attention for article published in Cochrane database of systematic reviews, January 2015
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (95th percentile)
  • High Attention Score compared to outputs of the same age and source (84th percentile)

Mentioned by

news
1 news outlet
twitter
33 tweeters
facebook
4 Facebook pages
wikipedia
2 Wikipedia pages

Citations

dimensions_citation
27 Dimensions

Readers on

mendeley
106 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Indacaterol, a once-daily beta2 -agonist, versus twice-daily beta2 -agonists or placebo for chronic obstructive pulmonary disease
Published in
Cochrane database of systematic reviews, January 2015
DOI 10.1002/14651858.cd010139.pub2
Pubmed ID
Authors

James B Geake, Eli J Dabscheck, Richard Wood-Baker, Christopher J Cates

Twitter Demographics

The data shown below were collected from the profiles of 33 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 106 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 2%
United States 1 <1%
Sweden 1 <1%
Unknown 102 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 17 16%
Student > Master 16 15%
Student > Bachelor 14 13%
Student > Ph. D. Student 13 12%
Student > Doctoral Student 10 9%
Other 21 20%
Unknown 15 14%
Readers by discipline Count As %
Medicine and Dentistry 55 52%
Nursing and Health Professions 11 10%
Pharmacology, Toxicology and Pharmaceutical Science 6 6%
Social Sciences 4 4%
Economics, Econometrics and Finance 3 3%
Other 12 11%
Unknown 15 14%

Attention Score in Context

This research output has an Altmetric Attention Score of 33. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 November 2018.
All research outputs
#535,767
of 13,897,020 outputs
Outputs from Cochrane database of systematic reviews
#1,607
of 10,751 outputs
Outputs of similar age
#12,659
of 296,617 outputs
Outputs of similar age from Cochrane database of systematic reviews
#39
of 248 outputs
Altmetric has tracked 13,897,020 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 10,751 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.4. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 296,617 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 248 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.